MedTrace Logo

A Trial Using CD133 Enriched Bone Marrow Cells Following Primary Angioplasty for Acute Myocardial Infarction

NCT00529932 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2015-04-22

No results posted yet for this study

Summary

An international, multi-centre, double-blind, randomised, placebo-controlled clinical trial with central core lab analyses to determine the safety of intra-coronary infusion of enriched CD133+, bone marrow-derived, autologous progenitor cells in patients 5-10 days after acute percutaneous coronary revascularization (primary PCI) for ST-segment elevation myocardial infarction (STEMI).

Conditions

  • Acute Myocardial Infarction

Interventions

OTHER

CD133+ infusion

Subjects will be infused with all available autologous CD133+ cells after processing during one infusion session (during angiography).

OTHER

placebo infusion

Buffered normal saline will be infused in the coronary artery during an angiography.

Sponsors & Collaborators

Principal Investigators

  • Jozef Bartunek, MD · OLVZ Aalst

  • Jonathan Hill, MD · King's College London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2011-12-31
Completion
2012-12-31

Countries

  • Belgium
  • France
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00529932 on ClinicalTrials.gov